Novel small molecules used to visualize prostate cancer

Two novel radiolabeled small molecules targeting prostate-specific membrane antigen (PSMA) have excellent potential for further development as diagnostic and therapeutic radiopharmaceuticals, according to research published this month in The Journal of Nuclear Medicine. The imaging agents—123I-MIP-1072 and 123I-MIP-1095—were shown to have a high sensitivity of lesion detection in bone, soft tissue and the prostate gland with minimal retention in non-target tissue.

An estimated 238,500 men will be diagnosed with in 2013, and 29,700 will die from the disease. Accurate diagnosis and staging of prostate cancer is critical to determining appropriate patient management. Patients with localized disease may benefit from a , while those with are typically treated with .

"Current imaging techniques have limitations in diagnosing and staging prostate cancer. New imaging approaches, including the radiolabeled small molecules 123I-MIP-1072 and 123I-MIP-1095, may assess disease status more accurately," said John J. Babich, PhD, lead author of the article "First-in-Man Evaluation of Two High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer." Babich continued, "Improved imaging approaches could better facilitate the selection of optimal treatment and improve patient outcomes."

Separate studies were conducted as part of phase 1 trials under an investigational new drug application to measure the potential effectiveness of the small molecules in diagnosing and staging prostate cancer. In the first study, seven patients with documented prostate cancer were administered doses of 123I-MIP-1072 and 123I-MIP-1095 two weeks apart. In the second study, six healthy volunteers received 123I-MIP-1072 only. Whole body planar imaging and single computed tomography (SPECT)/computed tomography (CT) were performed for each group, and pharmacokinetics, tissue distribution, excretion, safety and organ were analyzed.

Both 123I-MIP-1072 and 123I-MIP-1095 visualized lesions in soft tissue, bone and the prostate gland as early as one to four hours after injection. The imaging agents cleared the blood in a biphasic manner; however, clearance of 123I-MIP-1072 was approximately five times faster, resulting in a higher lesion-to-background ratio as compared to 123I-MIP-1095. The largest organ-absorbed radiation doses for 123I-MIP-1072 were to the urinary bladder, salivary glands, and kidneys; for 123I-MIP-1095 the absorbed doses to the salivary glands, kidneys and thyroid were the largest. Both imaging agents were well tolerated by the study population.

As a result of the phase 1 findings, 123I-MIP-1072 was evaluated as a diagnostic agent in subsequent clinical trials on the basis of its higher lesion-to-background ratios and prolonged tumor retention. 123I-MIP-1095 will be clinically evaluated for radiotherapy for metastatic prostate cancer as the 131I-labeled analog.

"A more accurate method of imaging prostate cancer and prostate cancer metastases would significantly impact the clinical management of men with prostate cancer. This would provide greater certainty as to the presence and extent of disease during the course of the patient's treatment," said Babich. "Data indicate that PSMA is an excellent target for molecular imaging of prostate cancer and that radiolabeled small molecules, which bind PSMA with high affinity, can localize prostate cancer anywhere in the body. The use of SPECT for molecular imaging could represent a significant advance in cancer evaluation."

More information: "First-in-Man Evaluation of Two High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer" The Journal of Nuclear Medicine.

add to favorites email to friend print save as pdf

Related Stories

'Smart bomb' drug delivery may increase effectiveness

Apr 21, 2009

Researchers may have found a way to combine imaging with chemotherapy in a single agent for the treatment of prostate cancer, according to data presented at the American Association for Cancer Research 100th Annual Meeting ...

Recommended for you

Mutations need help from aging tissue to cause leukemia

1 hour ago

Why are older people at higher risk for developing cancer? Prevailing opinion holds that, over time, your body's cells accumulate DNA damage and that eventually this damage catches up with the body in a way ...

Specific oxidation regulates cellular functions

6 hours ago

For a long time, hydrogen peroxide has been considered as a dangerous metabolite that can damage cells through oxidation. This, however, is not its only role in the cell. Scientists from the German Cancer Research Center ...

New disease mechanism discovered in lymphoma

6 hours ago

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.